1-4 of 4
Brian Druker, MD
Close
Sort by
Journal Articles

In Chronic Lymphocytic Leukemia, Zap70 Identifies a Survival Pathway Signal Cascade Involving p85 PI-3-Kinase, CrkL, and Cbl with Syk En Route to JNK1 and bcl-2.

Amy D. Hartman, MS, Annique Wilson-Weekes, MS, Larry D. Cripe, MD, Brydon Bennett, PhD, Glenn Friedman, PhD, Peter Worland, PhD, Brian Druker, MD, Shuyue Ren, PhD, Tomasz Skorski, PhD, H. Scott Boswell, MD
Journal: Blood
Blood (2006) 108 (11): 584.
https://doi.org/10.1182/blood.V108.11.584.584
Published: 2006
Journal Articles

Therapeutic Drug Monitoring of Imatinib and Impact on Clinical Decision Making.

Carolyn Blasdel, MA, RN, FNP, Yanfeng Wang, PhD, Theodore Lagattuta, BS, Brian Druker, MD, Laurie Letvak, MD, Merrill Egorin, MD FACP
Journal: Blood
Blood (2006) 108 (11): 4820.
https://doi.org/10.1182/blood.V108.11.4820.4820
Published: 2006
Journal Articles

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

Francois Guilhot, MD, Lydia Roy, MD, Joelle Guilhot, BS, Tillmann Krahnke, BSR, Agnes Guerci, MD, Brian Druker, MD, Richard Larson, MD, Steve O’Brien, MD, Charlene So, PharmD, Giorgio Massimini, MD
Journal: Blood
Blood (2005) 106 (11): 165.
https://doi.org/10.1182/blood.V106.11.165.165
Published: 2005
Journal Articles

Preliminary Results from a Phase 2 Trial of AG-858, an Autologous Heat Shock Protein-Peptide Vaccine, in Combination with Imatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Resistant to Prior Imatinib Monotherapy.

David Marin, MD, Michael Mauro, MD, John Goldman, MD, Brian Druker, MD, Steven Devine, MD, Richard E. Clark, MD, Ronald Paquette, MD, Asad Bashey, MD, Martin S. Tallman, MD, April Dovholuk, Axel Hoos, MD, PhD, Pramod Srivastava, PhD
Journal: Blood
Blood (2005) 106 (11): 1094.
https://doi.org/10.1182/blood.V106.11.1094.1094
Published: 2005